%0 Journal Article
%A Carceller, Fernando
%A Fowkes, Lucy A
%A Khabra, Komel
%A Moreno, Lucas
%A Saran, Frank
%A Burford, Anna
%A Mackay, Alan
%A Jones, David
%A Hovestadt, Volker
%A Marshall, Lynley V
%A Vaidya, Sucheta
%A Mandeville, Henry
%A Jerome, Neil
%A Bridges, Leslie R
%A Laxton, Ross
%A Al-Sarraj, Safa
%A Pfister, Stefan
%A Leach, Martin O
%A Pearson, Andrew D J
%A Jones, Chris
%A Koh, Dow-Mu
%A Zacharoulis, Stergios
%T Pseudoprogression in children, adolescents and young adults with non-brainstem high grade glioma and diffuse intrinsic pontine glioma.
%J Journal of neuro-oncology
%V 129
%N 1
%@ 1573-7373
%C Dordrecht [u.a.]
%I Springer Science + Business Media B.V
%M DKFZ-2017-01733
%P 109 - 121
%D 2016
%X Pseudoprogression (PsP) is a treatment-related phenomenon which hinders response interpretation. Its prevalence and clinical impact have not been evaluated in children/adolescents. We assessed the characteristics, risk factors and prognosis of PsP in children/adolescents and young-adults diagnosed with non-brainstem high grade gliomas (HGG) and diffuse intrinsic pontine gliomas (DIPG). Patients aged 1-21 years diagnosed with HGG or DIPG between 1995 and 2012 who had completed radiotherapy were eligible. PsP was assessed according to study-specific criteria and correlated with first-line treatment, molecular biomarkers and survival. Ninety-one patients (47 HGG, 44 DIPG) were evaluable. Median age: 10 years (range, 2-20). Eleven episodes of PsP were observed in 10 patients (4 HGG, 6 DIPG). Rates of PsP: 8.5 
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:27180091
%R 10.1007/s11060-016-2151-8
%U https://inrepo02.dkfz.de/record/125607